Purslane extract and glucose homeostasis in adults with type 2 diabetes: A double-blind, placebo-controlled clinical trial of efficacy and safety

Journal of Medicinal Food

Volumn 19, Issue 2, 2016, Pages 133-140

  Wainstein, Julio ^a   Landau, Zohar ^a   Dayan, Yosefa Bar ^a   Jakubowicz, Daniela ^a   Grothe, Torsten ^b   Perrinjaquet Moccetti, Tania ^b   Boaz, Mona ^a,c  

^a WOLFSON MEDICAL CENTER   (Israel)

^b Frutarom Switzerland Ltd   (Switzerland)

^c ARIEL UNIVERSITY   (Israel)

Author keywords

purslane; randomized clinical trial; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT EXTRACT; PURSLANE EXTRACT; REPAGLINIDE; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PORTULACACEAE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; HOMEOSTASIS; METABOLISM; MIDDLE AGED; PORTULACA;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLANT EXTRACTS; PORTULACA;

EID: 84958060578     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2015.0090     Document Type: Article

References (24)

1. Palaniswamy UR, Bible BB, McAvoy RJ: Effect of nitrate: Ammonium nitrogen ratio on oxalate levels of purslane. Trends New Crops New Uses 2002;11:453-455.
2. Lee AS, Kim JS, Lee YJ, Kang DG, Lee HS: Anti-TNF-α activity of Portulaca oleracea in vascular endothelial cells. Int J Mol Sci 2012;13:5628-5644.
3. Chan K, Islam MW, Kamil M, Radhakrishnan R, Zakaria MN, Habibullah M, Attas A: The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak. J Ethnopharmacol 2000;73:445-451.
4. Zhang XJ, Ji YB, Qu ZY, Xia JC, Wang L: Experimental studies on antibiotic functions of Portulaca oleracea L. in vitro. Chin J Microecol 2002;14:277-280.
5. Chen B, Zhou H, Zhao W, Zhou W, Yuan Q, Yang G: Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, PARα and FAS mRNA expression in highfat diet induced mice. Mol Biol Rep 2012;39:7981-7988.
6. Lans CA: Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus. J Ethnobiol Ethnomed 2006;2:45.
7. Jin R, Lin ZJ, Xue CM, Zhang B: An improved associationmining research for exploring Chinese herbal property theory: Based on data of the Shennong?s Classic of Materia Medica. J Integr Med 2013;11:352-365.
8. Gong F, Li F, Zhang L, Li J, Zhang Z, Wang G: Hypoglycemic effects of crude polysaccharide from Purslane. Int J Mol Sci 2009;10:880-888.
9. Lee AS, Lee YJ, Lee SM, Yoon JJ, Kim JS, Kang DG, Lee HS: An aqueous extract of Portulaca oleracea ameliorates diabetic nephropathy through suppression of renal fibrosis and inflammation in diabetic db/db mice. Am J Chin Med 2012;40:495-510.
10. El-Sayed MI: Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy. J Ethnopharmacol 2011;137:643-651.
11. Esmaillzadeh A, Zakizadeh E, Faghihimani E, Gohari M, Jazayeri S: The effect of purslane seeds on glycemic status and lipid profiles of persons with type 2 diabetes: A randomized controlled cross-over clinical trial. J Res Med Sci 2015;20:47-53.
12. Reid DP: Chinese Herbal Medicine. CFW Publications Ltd., Hong Kong, 1987.
13. Al-Bahrani AI, Bayoumi R, Al-Yahyaee SA: Lipids-risk categories in Omani type 2 diabetics: Impact of the national cholesterol educational program. Sultan Qaboos Univ Med J 2006; 6:19-25.
14. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
15. Nagao S, Yamaguchi T: PPAR-c agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Curr Mol Pharmacol 2012;5:292-300.
16. Burris TP, Busby SA, Griffin PR: Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 2012;19:51-59.
17. Floyd ZE, Stephens JM: Controlling a master switch of adipocyte development and insulin sensitivity: Covalent modifications of PPARc. Biochim Biophys Acta 2012;1822:1090-1095.
18. Sugawara A, Uruno A, Kudo M, Matsuda K, Yang CW, Ito S: Effects of PPARc on hypertension, atherosclerosis, and chronic kidney disease. Endocr J 2010;57:847-852.
19. Kung J, Henry RR: Thiazolidinedione safety. Expert Opin Drug Saf 2012;11:565-579.
20. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. J Am Med Assoc 2010; 304:411-418.
21. Lu Y, Ma D, Xu W, Shao S, Yu X: Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis. J Diabetes Investig 2015;6:78-86.
22. Suraci C, Mulas F, Rossi MC, Gentile S, Giorda CB: Management of newly diagnosed patients with type 2 diabetes: What are the attitudes of physicians? A SUBITO!AMD survey on the early diabetes treatment in Italy. Acta Diab 2012;49:429-433.
23. Albarracin CA, Fuqua BC, Evans JL, Goldfine ID: Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 2008;24:41-51.
24. Schedlowski M, Enck P, Rief W, Bingel U: Neuro-biobehavioral mechanisms of placebo and nocebo responses: Implications for clinical trials and clinical practice. Pharmacol Rev 2015;67:697-730.